CPHI — China Pharma Holdings Share Price
Last trade - 00:00- $5.47m
- $7.42m
- $7.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.73 | ||
| Price to Tang. Book | 1.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.78 | ||
| EV to EBITDA | 4,035.15 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.52% | ||
| Return on Equity | -52.43% | ||
| Operating Margin | -39.25% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 10.92 | 10.87 | 9.64 | 8.1 | 7.01 | n/a | n/a | -10.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
China Pharma Holdings Inc is a company principally engaged in the development, manufacture and marketing of pharmaceutical products. The Company's products are for human use in connection, and with a variety of high-incidence and high-mortality diseases and medical conditions prevalent. The Company manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. In addition, the Company is also engaged in the production of comprehensive healthcare products and protective products.
Directors
- Zhilin Li CHM (68)
- Heung Tsui DRC (64)
- Gene Bennett IND (73)
- Baowen Dong IND (80)
- Yingwen Zhang IND (76)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 28th, 1999
- Public Since
- February 15th, 2000
- No. of Shareholders
- 133
- No. of Employees
- 231
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 14,816,865
- Address
- 2nd Floor, No. 17, Jinpan Road, Haikou, HAIKOU, 570216
- Web
- http://www.chinapharmaholdings.com
- Phone
- +86 89866811730
- Auditors
- B F Borgers CPA PC
Upcoming Events for CPHI
Similar to CPHI
FAQ
As of Today at 19:05 UTC, shares in China Pharma Holdings are trading at $0.37. This share price information is delayed by 15 minutes.
Shares in China Pharma Holdings last closed at $0.37 and the price had moved by -78.58% over the past 365 days. In terms of relative price strength the China Pharma Holdings share price has underperformed the S&P500 Index by -82.7% over the past year.
There is no consensus recommendation for this security.
China Pharma Holdings does not currently pay a dividend.
China Pharma Holdings does not currently pay a dividend.
China Pharma Holdings does not currently pay a dividend.
To buy shares in China Pharma Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.37, shares in China Pharma Holdings had a market capitalisation of $5.47m.
Here are the trading details for China Pharma Holdings:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: CPHI
Based on an overall assessment of its quality, value and momentum China Pharma Holdings is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like China Pharma Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -48.5%.
As of the last closing price of $0.37, shares in China Pharma Holdings were trading -49.96% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The China Pharma Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
China Pharma Holdings' management team is headed by:
- Zhilin Li - CHM
- Heung Tsui - DRC
- Gene Bennett - IND
- Baowen Dong - IND
- Yingwen Zhang - IND